MarginsXMarginsX
Home › Markets › Health Care › TCRX

TScan Therapeutics Inc. (TCRX)

TCRX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.1451
-9.65% on the day
Market cap
$9.2M
Nano cap
Revenue · 2025
$10.3M
+266.7% on 2024
Net income · 2025
-$129.8M
-1256.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/0001193125-26-089884-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTCRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001783328
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$10.3M
Net income-$129.8M
Operating income-$135.8M
Net margin-1256.8%
Operating margin-1315.4%
Revenue growth+266.7%
Cash$152.4M
Total assets$228.8M
P/E (computed)Net income was not positive
P/S (computed)0.9×

Warning signs

Cash runway
7.9 months
$73.0M cash at September 30, 2026
Share count, 1 year
+19.4%
2025-10-31 to 2026-11-05
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$146K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$73.0M cash; operating cash flow -$27.7M a quarter.Report 2026-09-30
Shares outstanding67,779,255 (2026-11-05); 56,747,993 a year earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-09-02
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $146K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$586K-$33.1M-$27.1M$73.0M$33.0M$5.2M10-Q 2026-11-12
Q2 2026
2026-06-30
$1.1M-$30.4M-$27.5M$100.2M$32.8M$7.1M10-Q 2026-08-12
Q1 2026
2026-03-31
$982K-$28.7M-$24.3M$128.1M$32.7M$9.1M10-Q 2026-05-06
Q4 2025
2025-12-31
$2.6M-$23.0M-$32.0M$152.4M$32.5M$10.3M10-K 2026-03-04
Q3 2025
2025-09-30
$2.5M-$35.7M-$32.5M$169.5M$32.4M$8.4M10-Q 2026-11-12
Q2 2025
2025-06-30
$3.1M-$37.0M-$33.3M$169.4M$32.3M$7.0M10-Q 2026-08-12
Q1 2025
2025-03-31
$2.2M-$34.1M-$37.6M$154.1M$32.2M$4.4M10-Q 2026-05-06
Q4 2024
2024-12-31
$665K-$35.8M-$27.4M$178.7M$32.1M$2.8M10-K 2026-03-04

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-03-05
Latest annual report10-K2026-03-04
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-10-26

Source: SEC EDGAR submissions feed, 336 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-14.4%
1 month-25.8%
3 months-79.1%
Year to date-83.9%
1 year-85.8%
From 52-week high-88.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
INABIN8bio Inc.$0.8160-0.49%$8.8M
INTSIntensity Therapeutics Inc.$3.07-0.32%$10.1M
ALGSAligos Therapeutics Inc.$1.66-20.95%$10.4M
SCLXScilex Holding Company$1.25-12.59%$10.6M
BCDABioCardia Inc.$0.7901-4.92%$12.0M
DYAIDyadic International Inc.$0.3200-2.14%$12.8M
JSPRJasper Therapeutics Inc.$11.77-13.96%$13.1M
PASGPassage Bio Inc.$4.13-2.82%$13.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier